ATE219670T1 - Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia - Google Patents
Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxiaInfo
- Publication number
- ATE219670T1 ATE219670T1 AT97937714T AT97937714T ATE219670T1 AT E219670 T1 ATE219670 T1 AT E219670T1 AT 97937714 T AT97937714 T AT 97937714T AT 97937714 T AT97937714 T AT 97937714T AT E219670 T1 ATE219670 T1 AT E219670T1
- Authority
- AT
- Austria
- Prior art keywords
- acid
- dyspraxia
- treatment
- docohexaene
- production
- Prior art date
Links
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 title abstract 4
- 208000006888 Agnosia Diseases 0.000 title abstract 2
- 206010003062 Apraxia Diseases 0.000 title abstract 2
- 206010013976 Dyspraxia Diseases 0.000 title abstract 2
- 229940114079 arachidonic acid Drugs 0.000 title abstract 2
- 235000021342 arachidonic acid Nutrition 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 2
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9617847.0A GB9617847D0 (en) | 1996-08-27 | 1996-08-27 | Fatty acid treatment |
| PCT/GB1997/002282 WO1998008501A1 (en) | 1996-08-27 | 1997-08-26 | Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE219670T1 true ATE219670T1 (de) | 2002-07-15 |
Family
ID=10798969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97937714T ATE219670T1 (de) | 1996-08-27 | 1997-08-26 | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6184251B1 (de) |
| EP (1) | EP0956011B1 (de) |
| JP (1) | JP2001504086A (de) |
| KR (1) | KR20000035924A (de) |
| AT (1) | ATE219670T1 (de) |
| AU (1) | AU738117B2 (de) |
| CA (1) | CA2263839A1 (de) |
| DE (1) | DE69713620D1 (de) |
| GB (1) | GB9617847D0 (de) |
| IL (1) | IL128562A0 (de) |
| NO (1) | NO990934L (de) |
| NZ (1) | NZ334260A (de) |
| WO (1) | WO1998008501A1 (de) |
| ZA (1) | ZA977686B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
| GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| KR101205516B1 (ko) * | 2003-03-27 | 2012-11-28 | 산토리 홀딩스 가부시키가이샤 | 아라키돈산의 일내(日內) 리듬 정상화용 용도 |
| GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| EP2324828A1 (de) * | 2003-08-18 | 2011-05-25 | BTG International Limited | Behandlung neurodegenerativer Erkrankungen |
| WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
| JP2007524674A (ja) * | 2004-01-19 | 2007-08-30 | マーテック・バイオサイエンシーズ・コーポレーション | リーリン欠損症または機能障害およびそれに関連する方法 |
| GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
| GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
| ES2732293T3 (es) | 2007-02-22 | 2019-11-21 | Childrens Hospital & Res Center At Oakland | Formulaciones de ácidos grasos y métodos para el uso de las mismas |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP2211881A4 (de) * | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | Zusammensetzungen und verfahren zur prävention und behandlung von krankheiten von säugetieren |
| GB2460056A (en) * | 2008-05-14 | 2009-11-18 | Arab Science & Technology Foun | Compositions comprising omega-6 fatty acids for use in treating schistosomiasis |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0175468A3 (de) | 1984-08-10 | 1987-07-22 | Sentrachem Limited | Eicosanoide zur Verwendung bei der Krebstherapie |
| GB8813766D0 (en) | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| FR2653972B1 (fr) | 1989-11-07 | 1993-07-09 | Perrier Sante Sa | Phase grasse pour produits alimentaires et matieres alimentaires comparables a la creme contenant ladite phase grasse et leur procede de preparation. |
| GB9026648D0 (en) | 1990-12-07 | 1991-01-23 | Efamol Holdings | Nutrition |
| GB9217781D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| DE4304394A1 (en) | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
| CA2119000A1 (en) | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
| EP2140863A1 (de) | 1993-06-09 | 2010-01-06 | Martek Biosciences Corporation | Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung von neurologischen Störungen |
| GB9423625D0 (en) | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
-
1996
- 1996-08-27 GB GBGB9617847.0A patent/GB9617847D0/en active Pending
-
1997
- 1997-08-26 US US09/254,074 patent/US6184251B1/en not_active Expired - Fee Related
- 1997-08-26 NZ NZ334260A patent/NZ334260A/xx unknown
- 1997-08-26 KR KR1019997001660A patent/KR20000035924A/ko not_active Withdrawn
- 1997-08-26 JP JP51136998A patent/JP2001504086A/ja not_active Ceased
- 1997-08-26 DE DE69713620T patent/DE69713620D1/de not_active Expired - Lifetime
- 1997-08-26 IL IL12856297A patent/IL128562A0/xx unknown
- 1997-08-26 AU AU40247/97A patent/AU738117B2/en not_active Ceased
- 1997-08-26 CA CA002263839A patent/CA2263839A1/en not_active Abandoned
- 1997-08-26 EP EP97937714A patent/EP0956011B1/de not_active Expired - Lifetime
- 1997-08-26 AT AT97937714T patent/ATE219670T1/de not_active IP Right Cessation
- 1997-08-26 WO PCT/GB1997/002282 patent/WO1998008501A1/en not_active Ceased
- 1997-08-27 ZA ZA9707686A patent/ZA977686B/xx unknown
-
1999
- 1999-02-26 NO NO990934A patent/NO990934L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO990934L (no) | 1999-04-14 |
| AU4024797A (en) | 1998-03-19 |
| EP0956011B1 (de) | 2002-06-26 |
| IL128562A0 (en) | 2000-01-31 |
| GB9617847D0 (en) | 1996-10-09 |
| ZA977686B (en) | 1998-02-27 |
| AU738117B2 (en) | 2001-09-06 |
| CA2263839A1 (en) | 1998-03-05 |
| NO990934D0 (no) | 1999-02-26 |
| DE69713620D1 (de) | 2002-08-01 |
| EP0956011A1 (de) | 1999-11-17 |
| KR20000035924A (ko) | 2000-06-26 |
| NZ334260A (en) | 2000-08-25 |
| JP2001504086A (ja) | 2001-03-27 |
| WO1998008501A1 (en) | 1998-03-05 |
| US6184251B1 (en) | 2001-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE219670T1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
| ATE231885T1 (de) | Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura | |
| ATE332702T1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE205086T1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
| ATE330593T1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
| ATE204704T1 (de) | Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| ATE116848T1 (de) | Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris. | |
| DE69911380D1 (de) | Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen | |
| ATE269077T1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
| ATE274916T1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome | |
| ATE274349T1 (de) | Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs | |
| DE69921662D1 (de) | Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose | |
| DE69635298D1 (de) | Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen | |
| DE60115054D1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| DE69130679D1 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE3781054D1 (de) | Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen. | |
| ATE192929T1 (de) | Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis | |
| ATE226069T1 (de) | Verwendung von alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur behandlung von entzündlichen darmerkrankungen | |
| DE3787437D1 (de) | Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems. | |
| GR3020575T3 (en) | New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions | |
| ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| DE3578374D1 (de) | Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen. | |
| DE69630055D1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |